Mobile

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cance...

Mise à jour : Il y a 4 ans
Référence :

A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers: REZOLVE

  • | Pays :
  • Australia
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Critère d'inclusion

  • Advanced chemotherapy resistant gynaecological cancers ,Ascites

Liens